Letícia Telles Sales, MD

Medical Oncologist in Recife, Brasil. Particularly interested in breast and gynecological oncology, new developments in molecular oncology and survivorship.

[Yakup Ergün @dr_yakupergun]

HER2 positive mBC

Why ET Use and Randomization Start Time Matter

A slide from today’s meeting👇

[ESMO Open @ESMO_Open]

1st line ET plus palbociclib vs standard mono-CT in high-risk HR+ /HER2- metastatic BC and indication for CT: primary results from the randomized phase IV PADMA study in @ESMO_Open.ET+Palbociclib improved TTF and PFS, with higher hematological toxicity. https://t.co/EhNMUKJuoY

[Paolo Tarantino @PTarantinoMD]

ADCs enable an improved delivery of chemo, expanding its activity, but not necessarily decreasing its side effects. Why is that? How can we reduce the toxicities of ADCs?

Glad to share our @NatRevClinOncol article on how to optimize the safety of ADC! 🧵
https://t.co/QcpeKTosCq

[Paolo Tarantino @PTarantinoMD]

Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm

[Paolo Tarantino @PTarantinoMD]

🔥 🎯

[Daniel Castellano @cdanicas]

🎯🎯.- How to apply the current evidence in the treatment of mCSPC!! Excellent review.🙌
https://t.co/OFccsZ439w

👉.- The new molecular precision "triplet intensification" is here.
👉.- A HRR (BRCA2+) alt and pTEN loss population have a poor prognosis.
👉.- We need to better biomarkers profile in this setting
@OncoAlert @APCCC_Lugano @ANZUPtrials @myESMO @GuardConsortium @fedelosco

[Dr Rishabh Jain @DrRishabhOnco]

🧬 NGS is NOT just “detected” or “not detected.”
👉 The real question: Did we look properly?

🔹 Coverage = Did we look at that region?
🕳️ If an exon isn’t covered → it’s a blind spot.

🔹 Depth = How many times did we read it?
📉 Low depth = ↑ risk of missing low-frequency variants.

💡 Think of NGS like CCTV:
🎥 Coverage = How many cameras are installed?
🔁 Depth = How many times each frame was reviewed?

🚫 No camera? You missed the theft.
🤷‍♂️ Blurry frame? You can’t ID the culprit.

🔍 What to ask your lab (ALWAYS):
✔ % of target covered at ≥100x
✔ Mean & minimum depth per gene
✔ Any dropouts or low-confidence zones?

📊 Take-home:
➡️ Coverage = Where you looked
➡️ Depth = How well you looked

You need both to treat with confidence.

📖 Save this before your next MDT or tumor board.
🧬 More genomics insights coming 🔜

#OncoTwitter #MedTwitter #PrecisionOncology #NGS #Genomics #MolecularOncology
@OncoAlert @myesmo @esmo_open @ASCO

@tmprowell @vinrajs @marklewismd @oncology_bg @DrChoueiri @Liz_ORiordan @rsm2800 @mtmdphd @JackWestMD @JankovicK
```

[Paolo Tarantino @PTarantinoMD]

It used to take a decade to see so many changes in practice

Now it takes one single conference day.

#ESMO25 #ESMOAmbassadors

[Oncology Brothers @OncBrothers]

GI Cancer Highlights from #ASCO25 w/ @CathyEngMD

✅ #DYNAMIC3
✅ #ATOMIC
✅ #BREAKWATER
✅ #MATTERHORN
✅ #DESTINYGastric04

Full Discussion:
- https://t.co/YDUF2oqmDM
- Also on the “Oncology Brothers” podcast

#gism @ASCO #OncTwitter #MedTwitter

[Chiara Corti @CCortiMD]

Pleased to share the first series of pts who experienced recurrence on adjuvant abemaciclib+ET:

➤ 9.2% (15/163) recurred
➤ 50% ER loss post-tx
➤ 90% TP53-pathway alterations post-tx
➤ Median 1L m+ tx duration: 3.0 mo (IQR 1.6–5.0)

https://t.co/5Jpzq8uyc2

[Elia Seguí, MD @elia_segui]

#ASCO25: so many advances, but also so many questions. Quick takeaways and open questions from key breast cancer sessions👇:

[Letícia Telles Sales, MD @TellesSales]

@neoenergiabsb qi 29 lago sul sem energia ha cerca de 1 hora.. alguma previsao?

[rafaela ★ @fIeurwho]

toda vez que o rog aparece em beleza fatal eu tenho vontade de destruir minha tv

[Dr Amol Akhade @SuyogCancer]

So finally it is published. Much awaited Interlace trial for locally advanced ca cervix shows 8% OS benifit at the end of 5 years for neo adjuvant chemo followed by CTRT vs CTRT alone. HR 0.60
Now how will you fit keynote A18 into this- pembrolizumab with CTRT did show OS benifit with HR of 0.67 . @myESMO @Larvol @ASCO @BanerjeeSusana @5_utr @Larvol @brunolarvol @OncBrothers @OncoAlert

[Dr. AK 🇮🇳 @docakx]

🌟 ATRIAL FIBRILLATION - 17 simple rules for management

2024 ESC Guidelines for the management of atrial fibrillation

[Dr Amol Akhade @SuyogCancer]

Nice slide to show outcomes of perioperative chemo vs CTRT for all trials in GE junction and Stomach adenocarcinoma. Good for discussion with patient in clinic . @myESMO

[Letícia Telles Sales, MD @TellesSales]

@telles_sales ele que manda a real é essa

[✣ @dnorttt]

vcs não imaginam quantas coisas quero comprar e não compro. é uma batalha silenciosa.